Cargando…

Dexmedetomidine administration in a patient with status epilepticus under color density spectral array monitoring

BACKGROUND: Status epilepticus requires immediate treatment because treatment delay can cause permanent neurologic complications. Dexmedetomidine may be an option for the treatment of status epilepticus although its effect remains unclear with conflicting reports. CASE PRESENTATION: A 64-year-old wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Obara, Shinju, Kakinouchi, Koh, Honda, Jun, Noji, Yoshie, Hanayama, Chie, Murakawa, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967278/
https://www.ncbi.nlm.nih.gov/pubmed/32026959
http://dx.doi.org/10.1186/s40981-019-0234-1
_version_ 1783488919777574912
author Obara, Shinju
Kakinouchi, Koh
Honda, Jun
Noji, Yoshie
Hanayama, Chie
Murakawa, Masahiro
author_facet Obara, Shinju
Kakinouchi, Koh
Honda, Jun
Noji, Yoshie
Hanayama, Chie
Murakawa, Masahiro
author_sort Obara, Shinju
collection PubMed
description BACKGROUND: Status epilepticus requires immediate treatment because treatment delay can cause permanent neurologic complications. Dexmedetomidine may be an option for the treatment of status epilepticus although its effect remains unclear with conflicting reports. CASE PRESENTATION: A 64-year-old woman with epilepsy with complex partial seizures underwent total knee arthroplasty. After emergence from general anesthesia, she developed status epilepticus and was transferred to the intensive care unit. Following initial treatment using benzodiazepines, phenytoin, and levetiracetam, dexmedetomidine (0.37 μg/kg loading in 10 min followed by 0.6 μg/kg/h) was administered and seizures terminated in 20 min. Color density spectral array using Root® with SedLine® (Masimo, Irvine, CA, USA) showed an increase in power in high frequency band of the electroencephalogram during the seizure attacks. CONCLUSION: We described a case of status epilepticus which was treated with dexmedetomidine and monitored using color density spectral array.
format Online
Article
Text
id pubmed-6967278
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-69672782020-02-04 Dexmedetomidine administration in a patient with status epilepticus under color density spectral array monitoring Obara, Shinju Kakinouchi, Koh Honda, Jun Noji, Yoshie Hanayama, Chie Murakawa, Masahiro JA Clin Rep Case Report BACKGROUND: Status epilepticus requires immediate treatment because treatment delay can cause permanent neurologic complications. Dexmedetomidine may be an option for the treatment of status epilepticus although its effect remains unclear with conflicting reports. CASE PRESENTATION: A 64-year-old woman with epilepsy with complex partial seizures underwent total knee arthroplasty. After emergence from general anesthesia, she developed status epilepticus and was transferred to the intensive care unit. Following initial treatment using benzodiazepines, phenytoin, and levetiracetam, dexmedetomidine (0.37 μg/kg loading in 10 min followed by 0.6 μg/kg/h) was administered and seizures terminated in 20 min. Color density spectral array using Root® with SedLine® (Masimo, Irvine, CA, USA) showed an increase in power in high frequency band of the electroencephalogram during the seizure attacks. CONCLUSION: We described a case of status epilepticus which was treated with dexmedetomidine and monitored using color density spectral array. Springer Berlin Heidelberg 2019-02-27 /pmc/articles/PMC6967278/ /pubmed/32026959 http://dx.doi.org/10.1186/s40981-019-0234-1 Text en © The Author(s) 2019, Corrected publication 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Case Report
Obara, Shinju
Kakinouchi, Koh
Honda, Jun
Noji, Yoshie
Hanayama, Chie
Murakawa, Masahiro
Dexmedetomidine administration in a patient with status epilepticus under color density spectral array monitoring
title Dexmedetomidine administration in a patient with status epilepticus under color density spectral array monitoring
title_full Dexmedetomidine administration in a patient with status epilepticus under color density spectral array monitoring
title_fullStr Dexmedetomidine administration in a patient with status epilepticus under color density spectral array monitoring
title_full_unstemmed Dexmedetomidine administration in a patient with status epilepticus under color density spectral array monitoring
title_short Dexmedetomidine administration in a patient with status epilepticus under color density spectral array monitoring
title_sort dexmedetomidine administration in a patient with status epilepticus under color density spectral array monitoring
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967278/
https://www.ncbi.nlm.nih.gov/pubmed/32026959
http://dx.doi.org/10.1186/s40981-019-0234-1
work_keys_str_mv AT obarashinju dexmedetomidineadministrationinapatientwithstatusepilepticusundercolordensityspectralarraymonitoring
AT kakinouchikoh dexmedetomidineadministrationinapatientwithstatusepilepticusundercolordensityspectralarraymonitoring
AT hondajun dexmedetomidineadministrationinapatientwithstatusepilepticusundercolordensityspectralarraymonitoring
AT nojiyoshie dexmedetomidineadministrationinapatientwithstatusepilepticusundercolordensityspectralarraymonitoring
AT hanayamachie dexmedetomidineadministrationinapatientwithstatusepilepticusundercolordensityspectralarraymonitoring
AT murakawamasahiro dexmedetomidineadministrationinapatientwithstatusepilepticusundercolordensityspectralarraymonitoring